Novacana GmbH
Pharmaceutical Companies · Frankfurt am Main
Novacana GmbH is a pharmaceutical company based in Frankfurt am Main, Hesse, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Novacana GmbH Overview
Novacana GmbH is a Frankfurt-based pharmaceutical company specializing in the distribution and import of medical cannabis products for the German market. Frankfurt am Main, as an international financial and economic hub, offers ideal conditions for establishing a Europe-wide cannabis distribution network. With a strong focus on innovative therapies in pain management and support for patients with specific conditions, Novacana's importance within the industry is continually growing.
Field of Activity & Products
Novacana GmbH imports and distributes medical cannabis products (cannabis flowers and extracts) for the German pharmacy market. The products offered come from GMP-certified producers from the EU and third countries with the appropriate export permits. These stringent quality standards guarantee the safety and efficacy of the products. In addition to cannabis flowers, the company also offers a variety of extracts in different forms of administration to meet the specific needs of patients.
Medical cannabis is prescribed in Germany for patients with chronic pain, multiple sclerosis, Tourette syndrome, anorexia, and other conditions. Novacana's products are specifically tailored to therapeutic requirements and are developed in close collaboration with specialists. This ensures that treatments are evidence-based and patient-centered.
Regulation
Novacana GmbH holds a permit from the Cannabis Agency of the BfArM for the import and wholesale of medical cannabis. All activities are subject to the strict regulations of the Narcotics Act (BtMG). The company is supervised by the Hessian Ministry of Social Affairs and Integration, ensuring regulatory compliance and quality assurance of the products. Regular audits and inspections ensure that all processes, from import to distribution, comply with legal requirements.
Regulation in the area of medical cannabis products has gained importance in recent years, and Novacana plays an active role in not only meeting these standards but also actively shaping them. Commitment to transparency and quality has strengthened trust among medical professionals as well as patients.
Regional Significance and Market Development
In terms of regional significance, Novacana GmbH is a central player in Hesse and beyond. With an increase in patients benefiting from medical cannabis products, demand in the pharmacy market is growing. Novacana helps to bridge this gap by ensuring reliable access to high-quality products. The company collaborates with numerous pharmacies and medical facilities and supports them through training and information offerings to strengthen knowledge about the medical use of cannabis.
Furthermore, Novacana relies on a network of scientific partners to promote ongoing research and development. This also includes clinical trials aimed at evaluating the efficacy and safety of cannabis therapies. Through these initiatives, the company positions itself not only as a supplier but also as a pioneer in medical research.
Special Features and Future Prospects
A special feature of Novacana GmbH is its commitment to social responsibility. The company actively engages in awareness campaigns aimed at reducing stigma against medical cannabis. In collaboration with patient associations, Novacana organizes workshops and informational events to promote understanding and acceptance of cannabis as an alternative treatment option.
The future prospects for Novacana are promising. Given the growing acceptance and increasing demand for sustainable treatment options in the healthcare sector, it is expected that demand for medical cannabis products will continue to rise. In the coming years, Novacana plans to expand its product portfolio and explore new therapeutic indications, which is likely to further solidify the company's market position.
More information: Pharmaceutical companies in Hesse or all pharmaceutical companies in Germany on Sanoliste.
Frequently asked questions about Novacana GmbH
What does Novacana GmbH do?
Novacana GmbH is ein Großhandel for medicines with the Erlaubnis zum Handel with Betäubungswithteln. Er führt medicines and Nahrungsergänzung in seinem Sortiment. Dazu gehören also products with medizinischem Cannabis.
More Pharmaceutical Companies in Frankfurt am Main
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.